OPKO Biologics will host a symposium at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology and will present the complete 12-month pharmacokinetic, pharmacodynamic, safety and efficacy data of OPKO’s weekly long-acting growth hormone (hGH-CTP) in naïve growth hormone deficient children. The 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology is taking place in Tokyo, Japan from October 8-10.
The data to be presented include results for 53 naïve growth hormone deficient children completing twelve months of weekly treatment with hGH-CTP. This phase 2 study was a one year, dose finding study administering hGH-CTP to growth hormone deficient children once a week using Genotropin® as a daily comparator arm. The twelve months data confirm comparable response of hGH-CTP to daily Genotropin® as reflected by the twelve months IGF-1SDS profile, annual HV, HV SDS and safety profile.
OPKO’s symposium will be held on Friday, Oct. 10, 2015 at 1.30 pm.